The Neuroendocrine Tumor Research Foundation (NETRF) 2026 Mentored Research Award provides $150,000 over two years to support early-career investigators — postdoctoral or clinical research fellows — conducting mentored research on neuroendocrine tumors (NETs). For 2026, NETRF has increased this award from $100,000 to $150,000, reflecting the Foundation’s deepened commitment to building the next generation of NET researchers. The award places special emphasis on projects within NETRF’s three-pillar Research Roadmap: Early Detection, New Therapeutic Development, and Precision Medicine. Investigators new to the NET field who can translate promising approaches from other cancer or biomedical disciplines are particularly encouraged. No indirect costs are permitted. The LOI deadline is March 16, 2026 at 5:00 PM ET.
Eligibility Criteria:
- Must hold an MD, PhD, or MD/PhD (or equivalent) degree
- Must be in a full-time postdoctoral or clinical research fellowship position at time of application
- Must be conducting mentored research at a non-profit academic or research institution
- A qualified, senior mentor at the same (or a collaborating) institution is required
- Open to applicants globally; no citizenship or residency restrictions
- Research must focus on neuroendocrine tumors; small cell lung cancer, large cell neuroendocrine carcinoma, neuroendocrine prostate cancer, mesothelioma, and poorly differentiated NSCLC are excluded
- No indirect costs allowed
Funding Details:
- Award amount: $150,000 over two years (increased from $100,000 in 2025)
- No indirect costs permitted; all funds support direct project expenses
- Allowable costs: personnel (including awardee’s salary/stipend), supplies, equipment, and other direct research costs
- Project start date: January 2027
Deadline:
- Letter of Intent (LOI): March 16, 2026, 5:00 PM ET
- Invitation notifications: Early May 2026
- Full Proposal Deadline: June 22, 2026, 5:00 PM ET
- Award announcement: October–November 2026
- Submit via NETRF’s online grants portal
Contact / Further Information: